FAM83B Inhibitors
FAM83B inhibitors generally operate by attenuating vital cellular signaling pathways. Many target the EGFR signaling cascade; compounds such as Erlotinib, Gefitinib, Lapatinib, and Afatinib bind to the ATP-binding site of the EGFR tyrosine kinase, thereby reducing its activation. By doing so, these inhibitors can indirectly suppress FAM83B activity, as the protein functions downstream of EGFR. This method of action effectively disrupts the EGFR signaling pathway, leading to the indirect impairment of FAM83B.
Simultaneously, FAM83B inhibitors may target the PI3K/AKT signaling pathway, of which FAM83B is a part. Inhibitors such as PI-103, LY294002, Wortmannin, and GDC-0941 are potent PI3K inhibitors that reducing the activation of the PI3K/AKT pathway, thus indirectly inhibiting FAM83B. Additionally, AKT-specific inhibitors like MK-2206, AZD5363, Perifosine, and Triciribine operate by specifically inhibiting AKT, a key component of the PI3K/AKT pathway, indirectly leading to the functional inhibition of FAM83B.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib inhibits the EGFR tyrosine kinase by binding to its ATP-binding site, thus leading to the inhibition of the EGFR signaling pathway. FAM83B is downstream of EGFR and its function can be indirectly inhibited when EGFR signaling is disrupted. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Like Erlotinib, Gefitinib also inhibits EGFR by binding to its ATP-binding site. This inhibition can indirectly reduce the functional activity of FAM83B. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib inhibits EGFR and HER2/neu tyrosine kinases, leading to decreased downstream signaling, which can indirectly inhibit FAM83B. | ||||||
Afatinib-d4 | 850140-72-6 (unlabeled) | sc-481821 | 10 mg | $4665.00 | ||
Afatinib irreversibly inhibits EGFR, HER2 and HER4, leading to inhibition of these signaling pathways, indirectly decreasing the activity of FAM83B. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103 is a PI3K inhibitor, directly inhibiting the PI3K/AKT pathway where FAM83B is involved. This can hinder the functional activity of FAM83B. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a broad-spectrum PI3K inhibitor that indirectly inhibits FAM83B by reducing PI3K/AKT pathway activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that inhibits the PI3K/AKT pathway, leading to indirect inhibition of FAM83B. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
GDC-0941 is a potent PI3K inhibitor, leading to indirect inhibition of FAM83B through its role in the PI3K/AKT pathway. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
MK-2206 is an AKT inhibitor that affects the PI3K/AKT pathway, leading to indirect inhibition of FAM83B. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363 is another AKT inhibitor that indirectly inhibits FAM83B by reducing PI3K/AKT pathway activity. | ||||||